If Roche doesn’t use the money for an acquisition, it can wait until Jul 2010 and then buy back its own shares without incurring an interest rate step-up on the bonds. At the current share price, repurchasing its own shares would be highly accretive to EPS.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”